Open AccessImmunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival
Author(s) -
Vega Karlowee,
Vishwa Jeet Amatya,
Takeshi Takayasu,
Motoki Takano,
Ushio Yonezawa,
Yukio Takeshima,
Kazuhiko Sakamoto,
Kaoru Kurisu,
Fumiyuki Yamasaki
Publication year - 2019
Publication title -
pathobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.941
H-Index - 53
eISSN - 1423-0291
pISSN - 1015-2008
DOI - 10.1159/000496691
Subject(s) - ezh2 , atrx , methyltransferase , isocitrate dehydrogenase , glioma , immunohistochemistry , immunostaining , cancer research , histone , biology , medicine , pathology , microbiology and biotechnology , mutation , dna , genetics , methylation , biochemistry , enzyme , gene
The interaction of K27M mutation in histone H3 (H3K27M mutation) with polycomb repressive complex 2 (PRC2) is facilitated by the enhancer of zeste homolog 2 (EZH2). Subsequently, this interaction leads to the global reduction level of H3K27me3. We analyzed the EZH2 expression level in H3K27M mutation-positive tumors and revealed the association of high EZH2 expression with poor survival.